Navigation Links
POZEN Announces Positive Outcome for PA 325 Proof of Concept Study

CHAPEL HILL, N.C.--(BUSINESS WIRE)--Mar 6, 2007 - POZEN Inc. (NASDAQ: POZN), today announced top-line results of its "Safer Aspirin" PA 325 proof-of-concept study conducted during the fourth quarter of 2006. PA 325 is a patented formulation of 325mg of aspirin surrounded by a 20mg coating of an immediate release formulation of a proton pump inhibitor.

The PA 325, 28 day study, involved two groups of 40 subjects over the age of 50. Each subject was treated with either once a day commercially available enteric coated aspirin 325mg or PA 325. The primary endpoint was gastrointestinal damage as measured by the Lanza scoring system used in our previous PN studies. The results were highly significant with 10 percent of the PA group having Lanza 3 or 4 gastrointestinal damage, whereas 57.5 percent of the enteric coated aspirin group had this level of gastrointestinal damage. Furthermore, no ulcers were seen in the PA group, while 20 percent of subjects in the enteric coated aspirin 325mg group developed a gastric ulcer during the study. This difference was also statistically significant.

Dr. John R. Plachetka, chairman, president and chief executive officer stated, "The data from this first clinical study with PA 325 is very encouraging."

About POZEN

POZEN is a pharmaceutical company committed to developing therapeutic advancements for diseases with unmet medical needs where it can improve efficacy, safety, and/or patient convenience. POZEN's efforts are focused primarily on the development of pharmaceutical products for the treatment of acute and chronic pain and other pain-related conditions. POZEN has development and commercialization alliances with GlaxoSmithKline for the proposed product candidate Trexima(TM) combining sumatriptan, formulated with RT Technology(TM), and naproxen sodium in a single tablet for the acute treatment of migraine, which is currently under review by the United States Food and Drug Administration, and with AstraZeneca for proprietary fixed dose combinations of naproxen with the proton pump inhibitor esomeprazole magnesium in a single tablet for conditions such as osteoarthritis and rheumatoid arthritis in patients who are at risk for developing NSAID-associated gastric ulcers. The company's common stock is traded on The Nasdaq Stock Market under the symbol "POZN". For detailed company information, including copies of this and other press releases, see POZEN's website: www.pozen.com.

Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management's current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our failure to successfully commercialize our product candidates; costs and delays in the development and/or FDA approval of our product candidates, including as a result of the need to conduct additional studies, or the failure to obtain such approval of our product candidates, including as a result of changes in regulatory standards or the regulatory environment during the development period of any of our product candidates; uncertainties in clinical trial results or the timing of such trials, resulting in, among other things, an extension in the period over which we recognize deferred revenue or our failure to achieve milestones that would have provided us with revenue; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; our inability to obtain any additional required financing; technological changes; government regulation; changes in industry practice; and one-time events, including those discussed herein and in our Quarterly Report on Form 10-Q for the period ended September 30, 2006. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.

Contact

POZEN Inc.
Bill Hodges, 919-913-1030
Chief Financial Officer
or
Fran Barsky, 919-913-1044
Director, Investor Relations


'"/>




Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/20/2019)... ... 2019 , ... Aeroflow Healthcare, an Inc. 5000 fastest growing company, today announced ... Every Kid Healthy™ Week, to benefit Diaper Bank of North Carolina. The company encourages ... at 3165 Sweeten Creek Road in Asheville, N.C. Diapers in sizes 4, 5, and ...
(Date:3/20/2019)... ... March 20, 2019 , ... “Some years ago, when ... biofeedback had in Canada in preparing our military athletes for the annual competitions of ... different nations. I know also that today biofeedback is used to help servicemen prepare ...
(Date:3/20/2019)... ... March 20, 2019 , ... Becker's Hospital Review is pleased ... + Pharmacy Conference, held May 2-4 at the Swissotel in Chicago. The celebrity ... NFL Sunday and NFL Legend; ,     Bobbi Brown, Makeup Artist, Author, ...
Breaking Medicine Technology:
(Date:3/20/2019)... ... March 20, 2019 , ... Nike Softball Camp ... Slupinski will be leading the camp with her staff. , Coach Slupinski takes the ... Redlands where she was the head coach for 2 seasons. Slupinski had an impressive ...
(Date:3/20/2019)... ... 2019 , ... AutismOne has announced that Dr. Andrew Wakefield, an author and ... Wakefield's presentation at the AutismOne 2019 Conference will address what herd immunity is and ... lecture will examine the consequences - real and potential - for vaccines that do ...
(Date:3/20/2019)... , ... March 20, 2019 , ... Adam Equipment, a ... stand H77 at Forum Labo Paris from 26-28 March at Paris expo Porte de ... series and the Solis series of balances. Both balance lines include models ...
(Date:3/20/2019)... ... March 20, 2019 , ... Caring.com, the nation’s most visited website ... systems for 2019. The medical alert provider was recognized as the Best Standalone ... for the list based on its demonstration of excellent customer service, transparency and affordability. ...
(Date:3/19/2019)... ... ... Adult superstar, sex educator and exclusive Wicked Pictures contract star jessica drake and ... begin production on April 17 in Los Angeles. , Media members interested in attending ... Sex” brings together jessica drake with senior sex expert Joan Price as they take ...
Breaking Medicine News(10 mins):